CureVac N.V.

NASDAQ:CVAC   3:59:55 PM EDT
105.70
+5.30 (+5.28%)
4:35:11 PM EDT: $105.90 +0.20 (+0.19%)
Products

Curevac Covid-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against Sars-Cov-2 B.1.351 Variant

Published: 03/23/2021 12:07 GMT
CureVac N.V. (CVAC) - Curevac's Covid-19 Vaccine Candidate, Cvncov, Demonstrates Protection Against Sars-cov-2 B.
1.351 Variant (south African Variant) in Preclinical Challenge Study.
First Challenge Infection Study in Preclinical Mouse Model to Provide Evidence for Protection Against Sars-cov-2 Variant.
Cvncov Induces Robust Antibody Titers With Virus Variant Neutralizing Capacity in Immunized Animals.
Full Protection of Immunized Mice From Infection and Mortality During Variant Challenge Infection.